MedPharm and Tergus Pharma Merge to Create Topical & Transdermal CDMO Leader

July 8, 2024

MedPharm and Tergus Pharma have merged and will operate under the MedPharm name to create an integrated, end-to-end topical and transdermal CDMO. Ampersand Capital Partners and Bourne Partners Strategic Capital assume majority ownership of the combined company while Great Point Partners retains a significant minority stake; Michael Kane is appointed CEO and Patrick Walsh remains Executive Chairman.

Targets
MedPharm, Tergus Pharma
Industry
Pharmaceuticals
Location
United Kingdom
Transaction Type
Addon

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →